Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia
Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

How treatment with posttransplant maintenance tyrosine kinase inhibitors (TKIs) affects allogeneic hematopoietic stem cell transplantation for patients with high-risk Philadelphia chromosome-positive (Ph+) leukemia is not fully understood. Researchers, based at the Winship Cancer Institute, Emory University, Atlanta, sought to determine the effect of TKI therapy on this patient group.

The investigators followed the progress of 26 patients total (17 patients with Ph+ acute lymphoblastic leukemia and 9 patients with chronic myeloid leukemia) who received maintenance posttransplant therapy. The patients were treated with dasatinib, imatinib, nilotinib, or ponatinib, and treatment took place in the 10-year period from 2004 through 2014. TKI therapy was begun a median of 100 days following transplantation and the duration of therapy was 16 months (median).

TKI selection was determined according to estimated toxicities, pretransplantation response, and ABL1 domain mutations, if any. The median follow-up period was 3.6 years. The patient relapse-free survival rate was 61% after a 5-year period, and the overall survival rate was 78%. The 3 patients who subsequently experienced relapse were found to be disease-free after successful salvage treatment.

The research team concluded that TKI therapy following allogeneic hematopoietic stem cell transplantation may be beneficial, reducing the number of relapses for patients with advanced Ph+ leukemia.

Reference

1. DeFilipp Z, Langston A, Chen Z, et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk. 2016. doi: 10.1016/j.clml.2016.04.017. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs